Bayer Yakuhin and Japanese ophthalmology powerhouse Santen Pharmaceutical said on December 20 that they have extended their sales collaboration pact for the vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for an undisclosed term.They have been partnering in Japan for…
To read the full story
Related Article
- Bayer, Santen to Copromote VEGF Trap-Eye Injection
May 10, 2012
BUSINESS
- Shionogi to Buy Tanabe’s Edaravone Biz for US$2.5 Billion Upfront
December 23, 2025
- Asahi Kasei to Relocate R&D Base to Shonan iPark in January 2027
December 23, 2025
- Daiichi Begins Global PIII of Enhertu in Adjuvant Endometrial Cancer Use
December 23, 2025
- Enhertu Wins US Breakthrough Tag in Post-Neoadjuvant HER2 Breast Cancer
December 23, 2025
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





